GRAIL's financial position is reinforced by $435 million in new funding, including strategic backing from Samsung for ...
The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after 12 months. BridgeBio’s base case and upside targets for the muscle damage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback